

Special Issue

Immunomodulatory Effects of Drugs for Cancer Immunotherapy

Message from the Guest Editors

Recent advances in cancer immunotherapy, including those in immune checkpoint inhibitors (ICIs) or adoptive T-cell therapies, have contributed to better outcomes in cancer patients. However, even ICIs are ineffective in the treatment of certain cancers. Therefore, new strategies to enhance the efficacy of treatments are needed. It has been reported that several commonly used drugs, such as statin, exert immune-modulatory effects; due to such properties, these drugs are expected to enhance the body's immunity against cancer cells. This Special Issue aims to further develop the current body of literature on the current knowledge regarding the immunomodulatory effects of a wide variety of drugs, which will aid the advancement and development of cancer therapy. We are inviting submissions of review or original articles on all aspects of "Immunomodulatory Effects of Drugs for Cancer Immunotherapy".

Guest Editors

Dr. Maiko Matsushita

Division of Clinical Physiology and Therapeutics Keio University Faculty of Pharmacy 1-5-30, Shiba-koen, Minato-ku, Tokyo 105-8512, Japan

Dr. Takeshi Suzuki

Division of Basic Biological Science, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan

Deadline for manuscript submissions

closed (31 March 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/112320

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).